These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16271314)
1. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Modell JG; Rosenthal NE; Harriett AE; Krishen A; Asgharian A; Foster VJ; Metz A; Rockett CB; Wightman DS Biol Psychiatry; 2005 Oct; 58(8):658-67. PubMed ID: 16271314 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. Cox LS; Patten CA; Niaura RS; Decker PA; Rigotti N; Sachs DP; Buist AS; Hurt RD J Gen Intern Med; 2004 Aug; 19(8):828-34. PubMed ID: 15242467 [TBL] [Abstract][Full Text] [Related]
3. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Wilens TE; Haight BR; Horrigan JP; Hudziak JJ; Rosenthal NE; Connor DF; Hampton KD; Richard NE; Modell JG Biol Psychiatry; 2005 Apr; 57(7):793-801. PubMed ID: 15820237 [TBL] [Abstract][Full Text] [Related]
4. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695 [TBL] [Abstract][Full Text] [Related]
5. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of bupropion in winter depression: results of an open trial. Dilsaver SC; Qamar AB; Del Medico VJ J Clin Psychiatry; 1992 Jul; 53(7):252-5. PubMed ID: 1639745 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754 [TBL] [Abstract][Full Text] [Related]
8. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. Feighner J; Hendrickson G; Miller L; Stern W J Clin Psychopharmacol; 1986 Feb; 6(1):27-32. PubMed ID: 3081600 [TBL] [Abstract][Full Text] [Related]
9. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697 [TBL] [Abstract][Full Text] [Related]
10. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216 [TBL] [Abstract][Full Text] [Related]
11. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965 [TBL] [Abstract][Full Text] [Related]